Trial · NCT01729455
Results by group144
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 144
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Adverse Events of Special Interest (AESI) Using Initial Exposure Intent-to-Treat (ITT) Strategy | Benlysta | Mortality | 48 | Participants | |
| Number of Participants With Adverse Events of Special Interest (AESI) Using Initial Exposure Intent-to-Treat (ITT) Strategy | Non-Benlysta | Mortality | 29 | Participants | |
| Number of Participants With Adverse Events of Special Interest (AESI) Using Initial Exposure Intent-to-Treat (ITT) Strategy | Benlysta | Malignancies (excluding NMSC) | 44 | Participants | |
| Number of Participants With Adverse Events of Special Interest (AESI) Using Initial Exposure Intent-to-Treat (ITT) Strategy | Non-Benlysta | Malignancies (excluding NMSC) | 24 | Participants | |
| Number of Participants With Adverse Events of Special Interest (AESI) Using Initial Exposure Intent-to-Treat (ITT) Strategy | Benlysta | Serious infections | 167 | Participants | |
| Number of Participants With Adverse Events of Special Interest (AESI) Using Initial Exposure Intent-to-Treat (ITT) Strategy | Non-Benlysta | Serious infections | 65 | Participants | |
| Number of Participants With Adverse Events of Special Interest (AESI) Using Initial Exposure Intent-to-Treat (ITT) Strategy | Benlysta | Opportunistic infections | 38 | Participants | |
| Number of Participants With Adverse Events of Special Interest (AESI) Using Initial Exposure Intent-to-Treat (ITT) Strategy | Non-Benlysta | Opportunistic infections | 21 | Participants | |
| Number of Participants With Adverse Events of Special Interest (AESI) Using Initial Exposure Intent-to-Treat (ITT) Strategy | Benlysta | Other infections of special interest | 44 | Participants | |
| Number of Participants With Adverse Events of Special Interest (AESI) Using Initial Exposure Intent-to-Treat (ITT) Strategy | Non-Benlysta | Other infections of special interest | 19 | Participants | |
| Number of Participants With Adverse Events of Special Interest (AESI) Using Initial Exposure Intent-to-Treat (ITT) Strategy | Benlysta | NMSC | 10 | Participants | |
| Number of Participants With Adverse Events of Special Interest (AESI) Using Initial Exposure Intent-to-Treat (ITT) Strategy | Non-Benlysta | NMSC | 4 | Participants | |
| Number of Participants With Adverse Events of Special Interest (AESI) Using Initial Exposure Intent-to-Treat (ITT) Strategy | Benlysta | Serious psychiatric events | 26 | Participants | |
| Number of Participants With Adverse Events of Special Interest (AESI) Using Initial Exposure Intent-to-Treat (ITT) Strategy | Non-Benlysta | Serious psychiatric events | 5 | Participants | |
| Incidence Rate of AESI Up to 12 Months Using As-Exposed - Time Varying Strategy | Benlysta | Mortality | 0.50 | 95% Confidence Interval 0.23 to 0.95 | Events per 100 participant-years |
| Incidence Rate of AESI Up to 12 Months Using As-Exposed - Time Varying Strategy | Non-Benlysta | Mortality | 0.88 | 95% Confidence Interval 0.38 to 1.73 | Events per 100 participant-years |
| Incidence Rate of AESI Up to 12 Months Using As-Exposed - Time Varying Strategy | Benlysta | Malignancies | 0.55 | 95% Confidence Interval 0.27 to 1.02 | Events per 100 participant-years |
| Incidence Rate of AESI Up to 12 Months Using As-Exposed - Time Varying Strategy | Non-Benlysta | Malignancies | 0.66 | 95% Confidence Interval 0.24 to 1.44 | Events per 100 participant-years |
| Incidence Rate of AESI Up to 12 Months Using As-Exposed - Time Varying Strategy | Benlysta | Serious infections | 2.86 | 95% Confidence Interval 2.13 to 3.76 | Events per 100 participant-years |
| Incidence Rate of AESI Up to 12 Months Using As-Exposed - Time Varying Strategy | Non-Benlysta | Serious infections | 2.33 | 95% Confidence Interval 1.44 to 3.56 | Events per 100 participant-years |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01729455/results